Evidence map›Paper›PMID 21057492›Full record

ArticleNature2010

Direct conversion of human fibroblasts to multilineage blood progenitors.

Eva Szabo, Shravanti Rampalli, Ruth M Risueño, Angelique Schnerch, Ryan Mitchell, Aline Fiebig-Comyn, Marilyne Levadoux-Martin, Mickie Bhatia

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 346 papers.

0numbers the graph read from it
0cells of the map it votes in
346citing papers in PubMed
42.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

346 citing papers in PubMed, 688 citations in OpenAlex.

  1. Computational Network Analysis for Defining Transcriptional Programs.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Advances in fibroblast-based cardiac reprogramming in the treatment of heart disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Erythroid Cells as Full Participants in the Tumor Microenvironment.International journal of molecular sciences · 2023
    Review
  17. Review
  18. Article
  19. Endothelial cell direct reprogramming: Past, present, and future.Journal of molecular and cellular cardiology · 2023
    Review
  20. Article

286 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Eva SzaboStem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada L8N 3Z5.
Shravanti Rampalli
Ruth M Risueño
Angelique Schnerch
Ryan Mitchell
Aline Fiebig-Comyn
Marilyne Levadoux-Martin
Mickie Bhatia
McMaster University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

As is the case for embryo-derived stem cells, application of reprogrammed human induced pluripotent stem cells is limited by our understanding of lineage specification. Here we demonstrate the ability to generate progenitors and mature cells of the haematopoietic fate directly from human dermal fibroblasts without establishing pluripotency. Ectopic expression of OCT4 (also called POU5F1)-activated haematopoietic transcription factors, together with specific cytokine treatment, allowed generation of cells expressing the pan-leukocyte marker CD45. These unique fibroblast-derived cells gave rise to granulocytic, monocytic, megakaryocytic and erythroid lineages, and demonstrated in vivo engraftment capacity. We note that adult haematopoietic programs are activated, consistent with bypassing the pluripotent state to generate blood fate: this is distinct from haematopoiesis involving pluripotent stem cells, where embryonic programs are activated. These findings demonstrate restoration of multipotency from human fibroblasts, and suggest an alternative approach to cellular reprogramming for autologous cell-replacement therapies that avoids complications associated with the use of human pluripotent stem cells.

Indexed as

Cell DifferentiationCell Culture TechniquesDermisFibroblastsHematopoietic Stem CellsHumansPluripotent Stem CellsStem Cells

Identifiers

PMID21057492
OpenAlexW2058553784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.